Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TDP2 | O95551 | 4/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268993 | 0.79 | GAA (0.51) | GAA | |
| SCHEMBL30468397 | 0.76 | GAA (1.00) | GAATDP2PDE3BPDE3AMAOA | |
| SCHEMBL15353713 | 0.74 | PTPRC (0.44) | PTPRCMAOAMAOBPRKCIPBRM1 | |
| SCHEMBL3132084 | 0.74 | GAA (0.54) | GAATDP2MAOAMAOB | |
| SCHEMBL9214465 | 0.71 | GAA (0.55) | GAA | |
| SCHEMBL7951439 | 0.71 | GAA (0.48) | GAA | |
| SCHEMBL7951440 | 0.71 | GAA (0.44) | GAA | |
| SCHEMBL4976676 | 0.71 | PARP1 (0.52) | PDE3BPDE3APTPRCMAOAMAOB | |
| SCHEMBL21550076 | 0.70 | GAA (0.50) | GAA | |
| SCHEMBL15906664 | 0.70 | GAA (0.57) | GAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680127-B1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070117791-A1 | Bicyclic compounds | JOLIDON SYNESE | 2007-05-24 | — | — | US | disclosed |
| US-7173023-B2 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050107360-A1 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107360-A1 | Bicyclic compounds | MAOB, MAOA, XDH | GAA 298/4885TDP2 904/4885PDE3B 392/4885 |
| US-20070117791-A1 | Bicyclic compounds | MAOB, MAOA, XDH | GAA 380/4885TDP2 1029/4885PDE3B 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.